10/29
11:05 pm
imab
Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders
Neutral
Report
Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders
10/29
11:15 am
imab
I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform
Low
Report
I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform
10/28
10:00 am
imab
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
10/27
10:07 am
imab
I-Mab (NASDAQ:IMAB) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
I-Mab (NASDAQ:IMAB) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
10/27
10:07 am
imab
I-Mab (NASDAQ:IMAB) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
I-Mab (NASDAQ:IMAB) had its "buy" rating reaffirmed by analysts at HC Wainwright.
10/27
08:06 am
imab
I-Mab (NASDAQ:IMAB) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $6.00 price target on the stock.
Low
Report
I-Mab (NASDAQ:IMAB) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $6.00 price target on the stock.
10/24
08:06 am
imab
I-Mab (NASDAQ:IMAB) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $9.00 price target on the stock.
Medium
Report
I-Mab (NASDAQ:IMAB) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $9.00 price target on the stock.
10/23
10:00 am
imab
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
10/22
12:35 pm
imab
I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025
Low
Report
I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025
10/19
01:05 am
imab
Medium
Report
10/17
06:17 pm
imab
I-Mab (IMAB) Discusses Business Transformation Strategy and Plans for Accelerated Growth Transcript [Seeking Alpha]
Medium
Report
I-Mab (IMAB) Discusses Business Transformation Strategy and Plans for Accelerated Growth Transcript [Seeking Alpha]
10/17
02:25 pm
imab
I-Mab (NASDAQ:IMAB) had its price target raised by analysts at BTIG Research from $7.00 to $9.00. They now have a "buy" rating on the stock.
Low
Report
I-Mab (NASDAQ:IMAB) had its price target raised by analysts at BTIG Research from $7.00 to $9.00. They now have a "buy" rating on the stock.
10/17
03:21 am
imab
I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences
High
Report
I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences
10/16
04:33 pm
imab
I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences [Yahoo! Finance]
High
Report
I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences [Yahoo! Finance]
10/16
04:05 pm
imab
I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences
High
Report
I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences
10/14
07:53 am
imab
I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference [Yahoo! Finance]
Low
Report
I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference [Yahoo! Finance]
10/14
07:00 am
imab
I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
Medium
Report
I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
10/11
08:37 am
imab
I-Mab's (NASDAQ:IMAB) market cap surged US$52m last week, individual investors who have a lot riding on the company were rewarded [Yahoo! Finance]
High
Report
I-Mab's (NASDAQ:IMAB) market cap surged US$52m last week, individual investors who have a lot riding on the company were rewarded [Yahoo! Finance]
10/8
12:25 pm
imab
I-Mab (NASDAQ:IMAB) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
I-Mab (NASDAQ:IMAB) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
10/4
05:45 am
imab
I-Mab (NASDAQ:IMAB) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Low
Report
I-Mab (NASDAQ:IMAB) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
10/3
07:00 am
imab
I-Mab (NASDAQ:IMAB) was given a new $9.00 price target on by analysts at Leerink Partners.
Low
Report
I-Mab (NASDAQ:IMAB) was given a new $9.00 price target on by analysts at Leerink Partners.
9/15
05:31 pm
imab
Bispecific Antibodies in Oncology Market Forecast to Surge Over the Next Decade | DelveInsight
Low
Report
Bispecific Antibodies in Oncology Market Forecast to Surge Over the Next Decade | DelveInsight
9/15
05:31 pm
imab
Bispecific Antibodies in Oncology Market Forecast to Surge Over the Next Decade | DelveInsight
Low
Report
Bispecific Antibodies in Oncology Market Forecast to Surge Over the Next Decade | DelveInsight
9/11
05:02 am
imab
I-Mab (NASDAQ:IMAB) was given a new $7.00 price target on by analysts at New Street Research.
Medium
Report
I-Mab (NASDAQ:IMAB) was given a new $7.00 price target on by analysts at New Street Research.
9/9
08:03 am
imab
I-Mab (NASDAQ:IMAB) is now covered by analysts at BTIG Research. They set a "buy" rating and a $7.00 price target on the stock.
Medium
Report
I-Mab (NASDAQ:IMAB) is now covered by analysts at BTIG Research. They set a "buy" rating and a $7.00 price target on the stock.